Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials
Tianyao Gong, Lei Liu, Yufei Liu, Ke Liu, Yang Yang, Liuying Li & Chuantao Zhang
We conducted a meta-analysis to systematically review the efficacy and safety of pembrolizumab for advanced NSCLC. Databases were searched for randomized controlled trials (RCTs) treated with pembrolizumab till July 2021. Seven RCTs and 3988 patients were included. Our analysis suggests that pembrolizumab was more effective at improving PFS (HR, 0.59; 95% CI: 0.43–0.79; p = 0.0005), OS (HR, 0.65; 95% CI: 0.55–0.76; p ＜ 0.00001) and ORR (RR, 1.85; 95% CI: 1.64–2.09; p ＜ 0.00001)...
1 citation reported since publication in 2021.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see
our documentation.